European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig

View source ↗

Summary

EMA recommends additional measures to reduce the risk of blood vessel blockage with Iclusig (ponatinib), a cancer medicine, to improve patient safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Eosinophilic Leukemia

Drugs mentioned

• Iclusig (ponatinib)